A pair of clinical data sets gives Novartis confidence in a new formulation of the company’s gene therapy Zolgensma for the ...
Novartis AG (NYSE:NVS) announced safety and efficacy results from the Phase 3 program for investigational intrathecal ...
TipRanks on MSN5h
Novartis announces results from Phase III program for OAV101 ITNovartis (NVS) announced positive safety and efficacy results from the Phase III program for investigational intrathecal onasemnogene abeparvovec, ...
Baclofen 50mcg/mL, 500mcg/mL, 2000mcg/mL; for intrathecal inj; preservative-free. <4yrs: not established. ≥4yrs: Give test dose 1 st by intrathecal inj via spinal catheter or lumbar puncture ...
Hosted on MSN2mon
Novartis reports positive results for intrathecal ZolgensmaNovartis (NYSE:NVS) said a Phase 3 study of an intrathecal formulation of its gene therapy Zolgensma, also known as OAV101 IT, met its primary endpoint in the treatment of children with spinal ...
High-dose methotrexate (HD-MTX) with the modified Bonn protocol including intrathecal therapy is effective for patients less than 65 years old with primary central nervous system lymphoma (PCNSL), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback